TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02633930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: : given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin
Description: Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
Study: NCT05401643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xemio mobile application
Description: The study consists in a mHealth intervention provided through the Xemio mobile application for breast cancer survivors. This application is installed in the personal smartphones of the participants after they are randomized in the mHealth intervention group. The Xemio app components are symptom tracking, up-to-date calendar of events organized by patient's organizations, virtual talks with experts, articles regarding new information of the disease, physical activity tracking, and evidence-based information regarding symptoms, non-pharmacological treatments for side effects, and information about common drugs to treat breast cancer. The participants can freely use the Xemio mobile application for a total of 12 months.~The control group does not have access to the Xemio application for the duration of the study but they are offered access to it at the completion of the intervention. The participants of both arms continued to receive the usual care from their oncology teams.
Study: NCT03245385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Halobetasol propionate 0.05% topical spray
Description: Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
Study: NCT02932592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (i Pro 2 - Medtronic)
Description: This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
Study: NCT03156322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mL epidural initiation volume (bupivacaine + fentanyl)
Description: 5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mL epidural initiation volume (bupivacaine + fentanyl)
Description: 10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mL epidural initiation volume (bupivacaine + fentanyl)
Description: 20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
Study: NCT01547988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training Intervention
Description: The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Balance Training Intervention
Description: The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
Study: NCT00158340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help cognitive behavioral therapy (CBT)
Description: Participants receive eight sessions of guided self-help CBT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical care
Description: Control group participants receive treatment as usual.
Study: NCT01665339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preload diet
Description: All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control diet
Description: All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
Study: NCT04659395

Intervention type: OTHER
Group type: OTHER
Intervention: Emergency nurses
Description: Emergency nurses who are trained for one-day in ultrasound-guided femoral nerve block
Study: NCT03009682

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack.
Study: NCT02234063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Genetic Testing
Description: Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
Study: NCT05555992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Activation Mapping Guided Cardiac resynchronization therapy
Description: To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
Study: NCT03607188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib
Description: Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib
Description: Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib
Description: Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib
Description: Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkotinib
Description: Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
Study: NCT03120689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Live Surgery using VITOM
Description: The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Live Surgery without VITOM
Description: The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video viewing with VITOM
Description: They will view the 10-minute standardized video filmed with the VITOM® camera.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video viewing with standard handheld high-definition camera
Description: They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
Study: NCT02596126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiovascular Polypill
Description: Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.~Participants will receive one of the following cardiovascular polypill:~(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).~or~(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Prevention for Secondary CV
Description: ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
Study: NCT04842214

Intervention type: BEHAVIORAL
Intervention: Oncological Rehabilitation
Description: Multidimensional rehabilitation
Study: NCT02467517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo : sodium chloride
Study: NCT01715610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clavulin
Description: Patients will be randomized to the antibiotic or placebo arm via a random number generator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Randomization to Placebo
Description: Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Patients will be randomized to the antibiotic or placebo arm via a random number generator
Study: NCT04402437

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LP Block
Description: Subjects randomized to the lumbar plexus block group will receive a subcutaneous lidocaine skin wheal 3-4 cm lateral to midline on the operative side along the intercristal line. A nerve stimulator will be sent to 1-1.5mA and a stimulating needle inserted perpendicular to the skin. The needle will be advanced slowly until the quadriceps muscle is stimulated and maintained at less than 0.6mAs. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: Subjects randomized to the quadratus plexus block group will receive a subcutaneous lidocaine skin wheal that will be placed after ultrasound identification of external oblique, internal oblique, transverse abdominus and quadratus lumborum muscles. A needle will then be advanced under ultrasound guidance below the internal oblique aponeurosis and lateral to the quadratus lumborum muscle. Ropivacaine (20ml, 0.5%) will be injected slowly with frequent aspiration to rule out inadvertent intravascular needle placement. Local anesthetic injection will also be observed with real time ultrasound guidance.
Study: NCT04192084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microvascular partial toe transfer
Description: we will perform microvascular partial toe transfer for patients with traumatic amputation of one or more digits
Study: NCT00069784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (HOE901)
Description: Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine (HOE901)
Description: Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids (PUFA)
Description: Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 polyunsaturated fatty acids (PUFA)
Description: Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo gelatin capsules (containing olive oil) for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo gelatin capsules (containing olive oil) for oral administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reusable pen device for insulin injection
Study: NCT02848430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Humulus lupulus
Description: Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
Study: NCT00069784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reusable pen device for insulin injection
Study: NCT03952221

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous ultrasound therapy
Description: continuous US therapy once a day, 9 minutes/session for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed ultrasound therapy
Description: pulsed US therapy once a day, 9 minutes/session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: US and electrotherapy (sonotens)
Description: US and electrotherapy (transcutaneous electrical nerve stimulation) once a day, 10 minutes /session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, US: 3 MHz frequency, 0,5 W/cm2 SATA intensity, TENS: application in conventional mode at 100 Hz frequency and 100 μs wavelength

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham ultrasound therapy
Description: sham US therapy once a day for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 0 MHz frequency, 0 W/cm2 SATA intensity
Study: NCT03573908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linaclotide
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral capsule
Study: NCT00118092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01741454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg by mouth once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg by mouth once per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg by mouth once per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg by mouth once per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: 4 mg by mouth once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: 4 mg by mouth once a day.
Study: NCT02669095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lenses (Test)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lenses (Control)
Study: NCT04345458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prefilled liquid etanercept(Yisaipu)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prefilled liquid etanercept(Yisaipu)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lyophilized etanercept powder(Yisaipu)
Study: NCT00732602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GIP-infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium-chloride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLP-2 infusion
Study: NCT01555164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine tablet(s) administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match ranolazine
Description: Placebo to match ranolazine for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match metformin
Description: Placebo to match metformin for the duration of the study

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study: NCT02974816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glooko's mobile application
Description: Standard of care and Remote monitoring
Study: NCT00420758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement: fortified spread
Description: Provision of fortified spread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement: maize-soy flour
Description: Provision of corn-soy blend (maize-soy flour)
Study: NCT03034499

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-port sacrocolpopexy
Description: Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-port sacrocolpopexy
Description: Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
Study: NCT04131790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Behavioral Activation
Description: Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-Friendly Visiting
Description: Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
Study: NCT00849004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silicone gel
Description: silicone gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silicone gel
Description: silicone gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silicone sheet
Description: silicone sheet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silicone sheet
Description: silicone sheet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper tape
Description: paper tape

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper tape
Description: paper tape